| 000 | 01819 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515154358.0 | ||
| 264 | 0 | _c20090130 | |
| 008 | 200901s 0 0 eng d | ||
| 022 | _a1474-547X | ||
| 024 | 7 |
_a10.1016/S0140-6736(09)60070-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan Marrewijk, Corine J | |
| 245 | 0 | 0 |
_aEffect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cJan 2009 |
||
| 300 |
_a215-25 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntacids _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aDyspepsia _xclassification |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHistamine H2 Antagonists _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 | _aPain Measurement |
| 650 | 0 | 4 | _aPatient Dropouts |
| 650 | 0 | 4 |
_aProton Pump Inhibitors _xeconomics |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 700 | 1 | _aMujakovic, Suhreta | |
| 700 | 1 | _aFransen, Gerdine A J | |
| 700 | 1 | _aNumans, Mattijs E | |
| 700 | 1 | _ade Wit, Niek J | |
| 700 | 1 | _aMuris, Jean W M | |
| 700 | 1 | _avan Oijen, Martijn G H | |
| 700 | 1 | _aJansen, Jan B M J | |
| 700 | 1 | _aGrobbee, Diederik E | |
| 700 | 1 | _aKnottnerus, J André | |
| 700 | 1 | _aLaheij, Robert J F | |
| 773 | 0 |
_tLancet (London, England) _gvol. 373 _gno. 9659 _gp. 215-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/S0140-6736(09)60070-2 _zAvailable from publisher's website |
| 999 |
_c18598162 _d18598162 |
||